ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership

Appoints Jonathan Sacks and Bruce Felt to the Board

Lou Silverman to Succeed Greg Garrison as Chairman

Veradigm Inc. (OTCMKTS: MDRX) (“Veradigm” or the “Company”), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the “Board”) appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison’s retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Governance Committee.

Mr. Sacks is a Partner at Stonehill Capital Management LLC (“Stonehill”), where he has been for over 20 years, and brings deep financial expertise and strategic insight to the Board. At Stonehill he has led and managed debt and equity investments across many industries including healthcare and software. While at Stonehill, Mr. Sacks has had extensive experience investing in companies undergoing complex transitions such as accounting challenges, delistings, and capital structure changes. Stonehill, through funds it manages on behalf of institutional investors and others, is Veradigm’s largest shareholder.

Mr. Felt has served as Chief Financial Officer (CFO) at several public companies in the technology space, including most recently at Domo (NASDAQ: DOMO), a cloud software company that specializes in business intelligence tools and data visualization. During his nearly nine-year tenure as CFO, Mr. Felt oversaw the scaling of Domo’s enterprise cloud business and helped take the company public in 2018. Prior to Domo, he served as CFO at SAP SuccessFactors (NASDAQ: SFSF) and FullTime Software (NASDAQ: FTSW), overseeing the sales of both companies. He currently serves on the board of directors of Cambium Networks (NASDAQ: CMBM), including as Audit Committee Chair. Mr. Felt also previously served as lead independent director and Audit Committee Chair at Evolent Health (NYSE: EVH).

“Veradigm remains focused on strong governance and strategic oversight as we continue to drive innovation and seek to maximize value for our stockholders,” said Mr. Garrison. “On behalf of the entire Board, I am pleased to welcome Jonathan and Bruce, who bring deep leadership, financial stewardship, and technology experience to the Board. Additionally, we are confident that with Bruce’s extensive financial and accounting background, he is highly qualified to serve as Audit Committee Chair.”

Mr. Garrison continued “I am very pleased that Lou Silverman has agreed to assume the role of Chairman upon my departure. With Lou’s 30 years of leadership experience in health information technology and technology-enabled healthcare services, the Board is confident in his ability to lead the Board as it oversees Veradigm’s next phase.”

“It will be an honor to serve as Veradigm’s Chairman of the Board as the Company navigates this important time,” said Mr. Silverman. “I want to thank Greg for his leadership and vision, and I look forward to working closely with the rest of the Board as we focus on our priorities: remediating our material weaknesses and other internal control deficiencies, becoming current in our financial reporting, executing our growth strategy, and relisting our common stock."

The appointments of Messrs. Felt and Sacks to the Board satisfy Veradigm’s obligations under the February 2025 Cooperation Agreement with Kent Lake PR LLC.

About Veradigm®

Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube.

© 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.20
-4.90 (-1.97%)
AAPL  273.47
-1.78 (-0.65%)
AMD  258.92
+21.40 (9.01%)
BAC  54.11
+0.48 (0.90%)
GOOG  287.45
-4.29 (-1.47%)
META  609.01
-18.07 (-2.88%)
MSFT  511.14
+2.46 (0.48%)
NVDA  193.80
+0.64 (0.33%)
ORCL  226.99
-9.16 (-3.88%)
TSLA  430.60
-9.02 (-2.05%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.